Evidence map›Paper›PMID 37303740›Full record

ReviewOncology research2023

The tumor suppressor role and ceRNA network of miR-1294 in cancer.

Yunan Mao, Jinze Shen, L I Fang, Feng Zhu, Shiwei Duan

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yunan MaoDepartment of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, 310000, China.
Jinze ShenDepartment of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, 310000, China.
L I FangSir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, China.
Feng ZhuDepartment of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, 310000, China.
Shiwei DuanDepartment of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, 310000, China.
Zhejiang University · CNSir Run Run Shaw Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miRNAs are endogenous small RNAs that are important regulators of gene expression. miR-1294 was found to be significantly down-regulated in 15 cancers and regulated by 21 upstream regulators. miR-1294 affects the proliferation, migration, invasion, and apoptosis of cancer cells. The target genes of miR-1294 are involved in the PI3K/AKT/mTOR, RAS, and JAK/STAT signaling pathways. Six target genes of miR-1294 are the targets of a variety of drugs. Low expression of miR-1294 is associated with resistance to cisplatin and TMZ and a poorer prognosis in patients with ESCC, GC, EOC, PDAC, or NSCLC. Therefore, this work outlines the molecular mechanisms and provides a basis for the clinical significance of the tumor suppressor miR-1294 in cancer.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsApoptosisHumansPhosphatidylinositol 3-KinasesMicroRNAsMIRN1294 microRNA, humanPhosphatidylinositol 3-KinasesCancerceRNAExpressionmiR-1294PrognosisSignaling pathway

Identifiers

PMID37303740
PMCPMC10207999
OpenAlexW4322721875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.